<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6439">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01772303</url>
  </required_header>
  <id_info>
    <org_study_id>HO-H2H-01-2011</org_study_id>
    <nct_id>NCT01772303</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of HO/03/03 10-40 Micro Grams to Treat Hard to Heal Wounds</brief_title>
  <acronym>H2H</acronym>
  <official_title>An Open-Label, Prospective, Multicenter Study to Assess the Safety and Efficacy of HO/03/03 10-40 Micro Gram (Wound Size Dependence) Applied Topically for up to 24 Weeks in Subjects With Various Etiologies of Hard-to-Heal Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HealOr</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HealOr</source>
  <oversight_info>
    <authority>&quot;Institutional Review Board:Israel&quot;</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, prospective, open-label, outpatient study will assess the safety and
      efficacy of HO/03/03 10µg applied topically once daily for up to 24 weeks in up to 100
      subjects with Hard to Heal documented chronic wounds of various etiologies (pressure ulcers,
       diabetic ulcers, post operational wounds surgical incisions ulcers of rheumatoid arthritis
      and trauma wounds) of at least 4 weeks documentation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects with a wound size of up to 56.25 cm2 (inclusive) will be administered 1 vial of
      10 ml HO/03/03 10μg per administration. For each increase in wound size of up to 56.25 cm2
      an additional vial of HO/03/03 10 μg will be added up to a maximal wound size area of 225
      cm2 (will be measured by HealOr central reviewer) utilizing 40µg (4 vials) per
      administration. 15 min post treatment wounds will be dressed according to standard of care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to Heal</measure>
    <time_frame>up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>1.	75% wound closure by or on study week 24 (Time to Event Analysis of incidence and time to 75% wound closure).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound closure</measure>
    <time_frame>up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>1. Complete wound closure by or on week 24 (Time to Event Analysis of incidence and time to 100% wound closure).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hard to Heal Wounds</condition>
  <arm_group>
    <arm_group_label>HO/03/03 10-40 micro gram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topically treatment with HO/03/03 10-40µg once daily for up to 24 weeks. Subjects will receive treatment with HO/03/03 10µg at a dose of 1-4 vials (i.e. 10-40 µg/administration) daily depending on their wound size.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HO/03/03 10-40 µg</intervention_name>
    <description>HO/03/03 10-40µg once daily (Topically) for up to 24 weeks.</description>
    <arm_group_label>HO/03/03 10-40 micro gram</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years old and above.

          -  Chronic wounds that have &lt; 30% change in area from Screening

          -  Have single / multiple wounds;

          -  Have a Hard-to-Heal wound(s) of various etiologies

        Exclusion Criteria:

          -  Have a documented medical history of a significant cardiac, pulmonary,
             gastrointestinal, endocrine (other than Diabetes Mellitus type 1 or 2), hepatic or
             per the physician's discretion.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yair Alegranti</last_name>
    <phone>+972-54-3161581</phone>
    <email>yair@healor.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kira Olshvang</last_name>
    <phone>+972-54-3161572</phone>
    <email>kira@healor.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maccabi Health Services, Wound Clinic</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Raba</last_name>
      <phone>+972-50-2400362</phone>
      <email>raba_m@mac.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Hanna Kaufman, MD</last_name>
      <phone>+972-50-9063142</phone>
      <email>dr.kaufmanh1@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hanna Kaufman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 3, 2013</lastchanged_date>
  <firstreceived_date>January 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pressure Ulcers, diabetic Ulcers, post operational wounds</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
